Physician profile
Daniel Arsenault
NPI 1265675854
$1,161.18
in general payments reported to CMS, 2019-2025
25 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $123 · 2021: $12.60 · 2022: $36.31 · 2023: $119 · 2024: $216 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.95 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $201.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $122.05 | 2019-2025 | Imfinzi, Calquence |
| Varian Medical Systems, INC. | $110.59 | 2019 | |
| Novocure INC. | $78.70 | 2020-2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Janssen Biotech, INC. | $60.47 | 2025 | Rybrevant, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $56.47 | 2024-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $54.41 | 2024-2025 | Keytruda, Lynparza |
| Seagen INC. | $48.91 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $47.21 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $44.47 | 2020-2024 | Ultomiris |
| Genentech USA, INC. | $36.76 | 2023-2025 | Phesgo, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $33.32 | 2025 | |
| Blueprint Medicines Corporation | $28.71 | 2025 | Ayvakit |
| Kyowa Kirin, INC. | $24.49 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $24.11 | 2025 | Myrisk |
| Genmab U.S., INC. | $21.20 | 2024 | Tivdak |
| Servier Pharmaceuticals LLC | $20.18 | 2025 | |
| Eisai INC. | $18.54 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 2025 | Opdualag |
| Exelixis INC. | $16.56 | 2025 | Cabometyx |
| Genzyme Corporation | $16.29 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.77 | 2023 | Pyrukynd |
| Recordati_rare_diseases_inc. | $15.01 | 2025 | Sylvant |
| Amgen INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arsenault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.